EQT Life Sciences Exits Vivasure Medical for €100 Million Sale to Haemonetics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: PRnewswire
- Strategic Exit: EQT Life Sciences successfully exits its investment in Vivasure Medical through a €100 million cash sale to Haemonetics, marking a significant return on its investment since 2016 in the medical technology sector.
- Technological Innovation: Vivasure's PerQseal® Elite system utilizes a bioabsorbable patch to provide sutureless vascular closure solutions, which is expected to significantly enhance patient outcomes in structural heart and endovascular procedures, thereby driving market demand.
- Market Expansion: This acquisition strengthens Haemonetics' competitive position in the large-bore closure device market, leveraging Vivasure's advanced technology and clinical data to increase its market share in the rapidly growing structural heart and endovascular procedure sectors.
- Investment Returns: EQT Life Sciences is entitled to up to €85 million in contingent consideration based on Vivasure's sales growth and achievement of other milestones, reflecting the investment value and potential returns in the field of medical innovation.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 88.86 USD with a low forecast of 74.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
